Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs

1

Acquired Orphan Blood Diseases Therapeutics
Market to 2019 - Search for Disease Modifying
Drugs Central to Unlocking Premium Pricing
Potential

Published By GBI Research
Published January-2013
2
Description


GBI Research has released its latest research,
Acquired Orphan Blood Diseases Therapeutics
Market to 2019 - Search for Disease Modifying
Drugs Central to Unlocking Premium Pricing
Potential. The report provides insights into the
up-and-coming trends of a portion of the acquired
orphan blood disorder pharmaceutical market by
examining Idiopathic Thrombocytopenic Purpura
(ITP), Myelodysplastic Syndrome (MDS),
Myelofibrosis (MF), Paroxysmal Nocturnal
Hemoglobinuria (PNH) and Polycythemia Vera (PV)
in seven major markets the US, the top five
European countries (France, Germany, Italy, Spain
and the UK) and Japan. The report includes market
forecasts to 2019, detailed pipeline analysis,
in-depth profiling of major products and details
of recent industry deals. The report is built
using data and information sourced from
proprietary databases, primary and secondary
research, and in-house analysis by GBI Researchs
team of industry experts. The MF market will be
the fastest growing of the five markets during
the forecast period, at a Compound Annual Growth
Rate (CAGR) of 34 and reaching a total market
size of 1.1bn in 2019. MDS represents the
largest market, expected to reach 2.2bn by 2019.
3
Description


Scope - Current and future treatment trends for
three rare diseases - Market forecasts for five
rare diseases across seven major markets -
Analysis of the developmental pipelines for five
rare diseases - Information on recent industry
deals
4
Description

Reasons to buy - Understand how the inherited
orphan blood diseases market has developed and is
continuing to develop within the featured
markets - Predict which products are likely to be
most successful in the future - Gain an
understanding of the possible market available
for specific products
5
Table of Contents

• 1 Table of Contents
• 2 Acquired Orphan Blood Diseases - Introduction
• 3 Acquired Orphan Blood Diseases - Therapeutic
  Landscape
• 3.1 Paroxysmal Nocturnal Hemoglobinuria
• 3.1.1 Disease Overview
• 3.1.2 Revenues
• 3.1.3 Revenue Analysis by Country
• 3.1.4 Annual Cost of Therapy
• 3.1.5 Treatment Usage Patterns
• 3.1.6 Marketed Products
• 3.1.7 Market Drivers
• 3.1.8 Market Restraints
• 3.2 Paroxysmal Nocturnal Hemoglobinuria
  Research and Development
• 3.2.2 Trends in Paroxysmal Nocturnal
  Hemoglobinuria Pipeline

6
Table of Contents

• 3.3 Idiopathic Thrombocytopenic Purpura
• 3.3.1 Disease Overview
• 4 Acquired Orphan Blood Diseases - Strategic
  Consolidations
• 5 Acquired Orphan Blood Diseases - Appendix
• For inquiry, kindly contact at
  http//www.reportsandintelligence.com/enquire-abou
  t-report/132364
• To check table of contents of the research, Visit
  _at_ http//www.reportsandintelligence.com/acquired-
  orphan-blood-diseases-therapeutics-to-2019-search-
  for-disease-modifying-drugs-central-to-unlocking-p
  remium-pricing-potential-market/table-of-contents

7

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/acquired-orp
han-blood-diseases-therapeutics-to-2019-search-for
-disease-modifying-drugs-central-to-unlocking-prem
ium-pricing-potential-market
Stay With Us
TELEPHONE Direct 1 [phone] Toll Free
1 [phone]E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States